App presents vitals and lab measurements for cardiac risk patients to facilitate dialogue and help improve health outcomes KANSAS CITY, MO & DURHAM, NC. Aug. 23, 2018 (GLOBE NEWSWIRE) — Cerner, a global leader in health care technology, collaborated with Duke Clinical Research Institute to develop an atherosclerotic cardiovascular disease (ASCVD) Risk Calculator app, designed […]
TOKYO and NEW YORK, February 5, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today results from the Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC). The results show that the use of XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) […]
Analysis of 75 patients with median follow-up of more than a year demonstrated an overall remission rate of 81% Event-free survival and overall survival at six months were 73% and 90%, with median duration of remission not reached Kymriah was detected in patients up to 20 months, demonstrating long-term persistence Novartis is committed to bringing […]
London, UK – 26 January 2018 – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Shingrix for the prevention of shingles (herpes zoster) and post-herpetic neuralgia (PHN), the most common and often painful shingles-related complication, […]
30-Day Your Cancer Game Plan Challenge Helps Those Impacted by Cancer and the Patient Organizations That Support Them KENILWORTH, N.J. January 31, 2018 –(BUSINESS WIRE)–With an estimated 1.6 million Americans diagnosed in 2017 alone, cancer not only impacts those diagnosed but their friends and family as well. In recognition of World Cancer Day on Sunday, […]
Phase 1/2 Study Planned for 2018 FOSTER CITY, Calif. & SANTA MONICA, Calif.–(BUSINESS WIRE)–Jan. 18, 2018– Kite, a Gilead Company (Nasdaq: GILD), announced it has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the investigational combination of Yescarta™ (axicabtagene ciloleucel) and Pfizer’s utomilumab, a fully humanized 4-1BB agonist monoclonal antibody, in patients with […]
Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer Lynparza reduced the risk of disease progression or death by 42% compared to standard of care chemotherapy 12 January 2018 – AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that […]
Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma Paris and Tarrytown, N.Y. – January 8, 2018 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will accelerate and expand investment for the clinical development of the PD-1 (programmed cell death protein 1) antibody cemiplimab in oncology and dupilumab in Type 2 allergic diseases. […]
Companies aim to develop jointly-branded clinical decision support software for faster, more accurate, more confident decision-making, enabling earlier diagnosis and individualised treatment Partnership will apply advanced analytics to in-vivo data from GE’s medical imaging and monitoring equipment with in-vitro data from Roche’s biomarker, tissue pathology, genomics and sequencing portfolio Basel, 08 January 2018 – Roche […]
Companies join forces to advance predictive and prescriptive recommendations for people with diabetes INDIANAPOLIS and MOUNTAIN VIEW, Calif., Jan. 8, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Livongo Health, a leading consumer digital health company focused on empowering all people with chronic conditions to live better and healthier lives, today announced a strategic collaboration to study real-world evidence and […]